Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q4 2016 · 10-K
Revenue$4.45M$4.45M+2.0% vs Q4 2015 Net Income-$2.15M-$2.15MN/M vs Q4 2015 EPS Diluted-$0.06-$0.06N/M vs Q4 2015 Gross Profit$2,010,069+25.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived$191,186N/M Free Cash Flowderived-$372,758— Margins · derivedGross margin45.1%+8.5 pt vs Q4 2015
Operating margin-48.8%−20.3 pt vs Q4 2015
Net margin-48.2%−15.5 pt vs Q4 2015
ended Dec 31, 2016 · filed Mar 16, 2017 · 75 d after period end